lilly glp 1 drugs Eli stock soars on encouraging results for daily weight-loss pill Lilly's Double-Beat Widens the GLP-1

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Side Effects: As a GLP-1 therapy, common side effects are typically gastrointestinal, including nausea, vomiting, and diarrhea.

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication

Ozempic and Wegovy users focus on nausea and vomiting